Hasil Pencarian - Daniel Bergemalm

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD.

    Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD. oleh Daniel Bergemalm, Robert Kruse, Maria Sapnara, Jonas Halfvarson, Elisabeth Hultgren Hörnquist

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.

    Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles. oleh Erik Andersson, Daniel Bergemalm, Robert Kruse, Gunter Neumann, Mauro D'Amato, Dirk Repsilber, Jonas Halfvarson

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Platelet proteome and function in X−linked thrombocytopenia with thalassemia and <i>in silico</i> comparisons with gray platelet syndrome

    Platelet proteome and function in X−linked thrombocytopenia with thalassemia and <i>in silico</i> comparisons with gray platelet syndrome oleh Daniel Bergemalm, Sofia Ramström, Caroline Kardeby, Kjell Hultenby, Anna Göthlin Eremo, Carina Sihlbom, Jörgen Bergström, Jan Palmblad, Maria Åström

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients.

    Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. oleh Karin Forsberg, P Andreas Jonsson, Peter M Andersen, Daniel Bergemalm, Karin S Graffmo, Magnus Hultdin, Johan Jacobsson, Roland Rosquist, Stefan L Marklund, Thomas Brännström

    Diterbitkan 2010-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

    Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study oleh Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study

    Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study oleh Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Jenny Gunnarsson, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, David Öberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: